Sana Biotechnology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sana Biotechnology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($244.17M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($266.76M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | ($283.26M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($269.48M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($355.93M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($285.31M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($130.78M) | Mar 16, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($250.32M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($272.72M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | ($293.14M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($272.56M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($356.91M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($286.15M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($141.15M) | Mar 16, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $131.98M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $215.67M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $261.81M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $285.89M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $248.63M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $132.94M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $99.59M | Mar 16, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($143.83M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($223.15M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | ($253.58M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($290.05M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($251.05M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($137.98M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($85.52M) | Mar 16, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $938.0K | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $33.43M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $20.03M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $20.88M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $29.86M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $23.87M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $26.12M | Mar 16, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $416.89M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $501.02M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $565.30M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $822.72M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $730.30M | Mar 16, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.01M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $250.52M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $277.79M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $323.41M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $400.91M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $298.58M | Mar 16, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.88M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $250.50M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $287.51M | Mar 3, 2026 |
| FY2025 | Dec 31, 2022 | $499.32M | Mar 3, 2026 |
| FY2024 | Dec 31, 2021 | $728.50M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | ($421.18M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | ($142.54M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2018 | ($13.19M) | Mar 16, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.63M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $140.63M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $140.63M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $140.63M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $140.63M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $140.63M | Mar 16, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.85B) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($1.60B) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($1.34B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.05B) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($785.36M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($429.43M) | Mar 16, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.87M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $127.57M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $133.52M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $176.77M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $253.03M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $124.81M | Mar 16, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (21) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (21) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 266.73M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 223.92M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 197.86M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 191.02M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 184.93M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 16.17M | Mar 16, 2022 |